Amy E. Juedes

Array ( [id] => 16451071 [patent_doc_number] => 20200360497 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => COMPOSITIONS AND METHODS FOR PRODUCING DENDRITIC CELLS [patent_app_type] => utility [patent_app_number] => 16/942058 [patent_app_country] => US [patent_app_date] => 2020-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18921 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16942058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20401200 [patent_doc_number] => 12491159 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-09 [patent_title] => Controlled release formulations for the induction and proliferation of blood cells [patent_app_type] => utility [patent_app_number] => 16/942656 [patent_app_country] => US [patent_app_date] => 2020-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 29 [patent_no_of_words] => 13275 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16942656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19248748 [patent_doc_number] => 20240199735 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => Microfibrillar-Associated Protein 5 (MFAP5)-Targeting Monoclonal Antibodies and Methods for Use in Treating Cancer [patent_app_type] => utility [patent_app_number] => 16/936421 [patent_app_country] => US [patent_app_date] => 2020-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21096 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16936421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16397269 [patent_doc_number] => 20200338127 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => Th1 vaccination priming for active immunotherapy [patent_app_type] => utility [patent_app_number] => 16/928884 [patent_app_country] => US [patent_app_date] => 2020-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8272 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16928884 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17895443 [patent_doc_number] => 20220305105 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => STABILIZED CHIMERIC SYNTHETIC PROTEINS AND THERAPEUTIC USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/618065 [patent_app_country] => US [patent_app_date] => 2020-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10407 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17618065 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17297842 [patent_doc_number] => 20210393681 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => Treatment of SARS-CoV-2 with Dendritic Cells for Innate and/or Adaptive Immunity [patent_app_type] => utility [patent_app_number] => 16/907335 [patent_app_country] => US [patent_app_date] => 2020-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32544 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16907335 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18717889 [patent_doc_number] => 11795220 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-24 [patent_title] => Anti-PVRIG antibodies and methods of use [patent_app_type] => utility [patent_app_number] => 16/904510 [patent_app_country] => US [patent_app_date] => 2020-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 220 [patent_figures_cnt] => 330 [patent_no_of_words] => 66265 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16904510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19580059 [patent_doc_number] => 12146159 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-19 [patent_title] => Methods for obtaining regulatory t cells and uses thereof [patent_app_type] => utility [patent_app_number] => 16/899142 [patent_app_country] => US [patent_app_date] => 2020-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 21 [patent_no_of_words] => 9842 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16899142 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16613714 [patent_doc_number] => 20210032367 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => ANTIBODIES AGAINST HUMAN CD39 AND USE THEREOF FOR INHIBITING T REGULATORY CELLS ACTIVITY [patent_app_type] => utility [patent_app_number] => 16/880835 [patent_app_country] => US [patent_app_date] => 2020-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10410 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16880835 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16437352 [patent_doc_number] => 20200354678 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => T-REG Cell Expansion [patent_app_type] => utility [patent_app_number] => 16/879923 [patent_app_country] => US [patent_app_date] => 2020-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14431 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16879923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16435668 [patent_doc_number] => 20200352993 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => DELIVERY OF ONCOLYTIC VIRUSES USING DENDRITIC CELLS [patent_app_type] => utility [patent_app_number] => 16/868691 [patent_app_country] => US [patent_app_date] => 2020-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7273 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16868691 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17733352 [patent_doc_number] => 20220218811 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => METHODS OF TREATING TUBERCULOSIS [patent_app_type] => utility [patent_app_number] => 17/594401 [patent_app_country] => US [patent_app_date] => 2020-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29920 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -87 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17594401 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16375063 [patent_doc_number] => 20200323905 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => METHODS AND COMPOSITIONS FOR MODULATING THE IMMUNE SYSTEM [patent_app_type] => utility [patent_app_number] => 16/849591 [patent_app_country] => US [patent_app_date] => 2020-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48724 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16849591 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20357547 [patent_doc_number] => 12473534 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-18 [patent_title] => Composition for culturing peripheral blood monocyte-derived regulatory t cell and regulatory T cell culturing method using same [patent_app_type] => utility [patent_app_number] => 17/762836 [patent_app_country] => US [patent_app_date] => 2020-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 0 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17762836 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16208013 [patent_doc_number] => 20200241003 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => T-CELL EPITOPE IDENTIFICATION [patent_app_type] => utility [patent_app_number] => 16/841943 [patent_app_country] => US [patent_app_date] => 2020-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11354 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16841943 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20328561 [patent_doc_number] => 12458818 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-04 [patent_title] => Anti-trophoblast cell surface antigen 2 (TROP2) antibodies and antibody drug conjugates comprising same [patent_app_type] => utility [patent_app_number] => 17/437423 [patent_app_country] => US [patent_app_date] => 2020-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 11 [patent_no_of_words] => 36318 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 176 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17437423 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16268844 [patent_doc_number] => 20200270331 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => IMMUNOGENIC PEPTIDES AND THEIR USE IN TRANSPLANTATION [patent_app_type] => utility [patent_app_number] => 16/804288 [patent_app_country] => US [patent_app_date] => 2020-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16405 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16804288 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16398824 [patent_doc_number] => 20200339682 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => ANTI-ILT7 ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/799441 [patent_app_country] => US [patent_app_date] => 2020-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24008 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16799441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16206588 [patent_doc_number] => 20200239578 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => BTLA AGONIST ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/792396 [patent_app_country] => US [patent_app_date] => 2020-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9293 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16792396 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17578794 [patent_doc_number] => 20220135649 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => DOMINANT NEGATIVE CD40L POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 17/427518 [patent_app_country] => US [patent_app_date] => 2020-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42666 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17427518 [rel_patent_id] =>[rel_patent_doc_number] =>)